Reported Earlier, FDA Approves Johnson & Johnson's IMAAVY (Nipocalimab-Aahu) As First-Ever Treatment For Warm Autoimmune Hemolytic Anemia, Based On Pivotal Phase 2/3 ENERGY Study

뉴스 본문을 불러오고 있어요.

Reported Earlier, FDA Approves Johnson & Johnson's IMAAVY (Nipocalimab-Aahu) As First-Ever Treatment For Warm Autoimmune Hemolytic Anemia, Based On Pivotal Phase 2/3 ENERGY Study | 웨이프 WAPE

Reported Earlier, FDA Approves Johnson & Johnson's IMAAVY (Nipocalimab-Aahu) As First-Ever Treatment For Warm Autoimmune Hemolytic Anemia, Based On Pivotal Phase 2/3 ENERGY Study

기사 요약

관련 종목

댓글 —